HER2-positive breast cancer accounts for about 20% of breast cancer cases and is generally associated with more aggressive ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

The approval covers the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult patients.

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial. Two new indications bring Daiichi Sankyo and ...

Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with ...

HER2-positive cancer cells produce HER2 protein that stimulates cell growth. Stage 4 HER2-positive esophageal cancer has a poor outlook, but some targeted therapy drugs may help people live longer.

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

Enhertu was approved for both neoadjuvant and adjuvant treatment in patients with HER2-positive early breast cancer. The Food and Drug Administration (FDA) has expanded the approval of Enhertu ® ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...